The Chief Executive Officer of Tyra Biosciences is D. Kirby Bullock, who guides the precision oncology company in developing targeted therapies designed to overcome drug resistance in precision medicine. Under his executive leadership, the organization focuses on advancing its proprietary in-house drug discovery platform, managing clinical trials, and expanding its corporate pipeline targeting specific oncology indications. His operational oversight ensures strict alignment between scientific discovery milestones and corporate strategic growth objectives.